NASA confirms stunning discovery of Space Shuttle Challenger artifact

recovered wreckage

Divers off the east coast of Florida have found an artifact underwater that NASA confirms is debris from the space shuttle Challenger. Photo courtesy of NASA

A TV documentary crew has just made a startling discovery linked to one of the American space program's greatest tragedies, one that deeply resonated here in Space City. Divers off the east coast of Florida have found an artifact underwater that NASA confirms is debris from the space shuttle Challenger.

While searching for wreckage of a World War II-era aircraft, documentary divers noticed a large object covered partially by sand on the seafloor, one that was clearly crafted by humans. The team contacted NASA after analyzing the proximity to the Florida Space Coast, the item’s modern construction, and presence of 8-inch square tiles, according to the space agency.

Upon viewing the TV crew's footage, NASA leaders confirmed the object is indeed part of the Challenger, which exploded during launch on January 28, 1986, killing all seven crew members on board — all of whom trained in Houston.

A History Channel documentary depicting the discovery of the Challenger artifact is scheduled to air Tuesday, November 22. While the episode will screen as part of a series about the Bermuda Triangle, the artifact was found well northwest of the area popularly known as the Bermuda Triangle, researchers note.

NASA, meanwhile, is currently considering what additional actions it may take regarding the artifact that will properly honor the legacy of Challenger’s fallen astronauts and their families, the agency notes.

The Challenger disaster is now counted as one of American history's "where were you?" moments. The mission, dubbed STS-51L, was commanded by Francis R. “Dick” Scobee and piloted by Michael J. Smith. The other crew members on board were mission specialists Ronald E. McNair; Ellison S. Onizuka, and Judith A. Resnik; payload specialist Gregory B. Jarvis; and teacher S. Christa McAuliffe.

Space Shuttle Challenger crew 1986The Challenger crew poses ahead of the mission in January, 1986. Photo courtesy of NASA


McAuliffe, a charismatic civilian with a bright smile, became an international celebrity, bringing everyman accessibility to the space program. She was beloved by fans young and old, and quickly became the face of the doomed mission.

Celebrating NASA's 25th shuttle mission, the spacecraft waited overnight on Launch Pad 39B at NASA’s Kennedy Space Center in Florida. A sudden coastal cold front brought freezing temperatures, causing ice to form on the shuttle. Launch managers cleared the mission for launch at 11:38 am on January 28, despite concerns raised by some shuttle program employees.

A mere 73 seconds after liftoff, major malfunction caused the explosion that killed the seven crew members, a moment captured on live TV and watched by millions.

Later, a NASA investigation revealed that the unexpectedly cold temperatures affected the integrity of O-ring seals in the solid rocket booster segment joints, sparking the explosion.

Challenger's loss, and later Columbia with its seven astronauts – which broke up on reentry in February 2003 over the western United States – greatly influenced NASA’s culture regarding safety. The agency went on to create an Office of Safety and Mission Assurance, developed new risk assessment procedures, and established an environment in which everyone can raise safety concerns.

NASA also created the Apollo Challenger Columbia Lessons Learned Program to share these lessons within the agency and with other government, public, commercial, and international audiences.

“While it has been nearly 37 years since seven daring and brave explorers lost their lives aboard Challenger, this tragedy will forever be seared in the collective memory of our country,” said NASA Administrator Bill Nelson in a statement. “For millions around the globe, myself included, January 28, 1986, still feels like yesterday. This discovery gives us an opportunity to pause once again, to uplift the legacies of the seven pioneers we lost, and to reflect on how this tragedy changed us. At NASA, the core value of safety is – and must forever remain – our top priority, especially as our missions explore more of the cosmos than ever before.”

By law, all space shuttle artifacts are the property of the U.S. government. Members of the public who believe they have encountered any space shuttle artifacts should contact NASA at ksc-public-inquiries@mail.nasa.gov to arrange for return of the items.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston health tech innovator collaborates on promising medical device funded by DOD

team work

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect.

The team working on this new research seeks to minimize near-eventualities like blood clot formation, blood damage, and driveline complications such as infection and limitations in mobility. The four institutions will try to innovate with a device featuring new engineering designs, antithrombotic slippery hydrophilic coatings (SLIC), wireless power transfer systems, and magnetically levitated driving systems.

Wang and her team believe that the non-contact-bearing technology will help to decrease the risk of blood clotting and damage when implanting an LVAD. The IDEA Lab will test the efficacy and safety of the SLIC LVAD developed by the multi-institutional team with a lab-bench-based blood flow loop, but also in preclinical models.

“The Texas Heart Institute continues to be a leading center for innovation in mechanical circulatory support systems,” said Joseph G. Rogers, MD, the president and CEO of THI, in a press release.

“This award will further the development and testing of the SLIC LVAD, a device intended to provide an option for a vulnerable patient population and another tool in the armamentarium of the heart failure teams worldwide.”

If it works as hypothesized, the SLIC LVAD will improve upon current LVAD technology, which will boost quality of life for countless heart patients. But the innovation won’t stop there. Technologies that IDEA Lab is testing include wireless power transfer for medical devices and coatings to reduce blood clotting could find applications in many other technologies that could help patients live longer, healthier lives.

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."



An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

View All Listings